News
Please, enter cell line, author or any other phrase or word you would like to search for.
BioStock: PHI expands market potential with regenerative medicine opportunity
BioStock contacted CFO Patrik Eschricht to find out more about PHI’s visions regarding regenerative medicine, cell-based therapies and automatization of biomanufacturing.
Interim Report 1 2022/23
Despite a summer-sluggish period ending in July, sales were just one unit away from surpassing our best quarter ever; the same period last year.
Wake Forest Institute for Regenerative Medicine Welcomes PHI
PHI visits the WFIRM to finalize an agreement concerning the automation of advanced quality control in large-scale biomanufacturing of regenerative therapies.
Year-end Report 2021/22
Sales more than doubled in 2021/22, compared to previous financial year.
Synthetic antibody patent awarded to PHI by Japan
PHI announces today that the Company has been granted a patent concerning synthetic antibodies in Japan.
PHI Enters Biomanufacturing Partnership with Wake Forest Institute for Regenerative Medicine
PHI and Wake Forest Institute for Regenerative Medicine recently signed a letter of intent outlining a biomanufacturing initiative to make indispensable imaging techniques available for regenerative medicine and large-scale production of cell therapies and organs.
PHI Signs Subscription Commitments with Board Members, CEO and Owners
Subscription commitments corresponding to approximately 4 % of the initial rights issue (2.9 million SEK) have been signed with members of the company’s board, the company’s CEO and with owners.
BioStock: PHIs CEO eyes new business opportunities
BioStock contacted CEO Peter Egelberg to find out more about the rights issue of just over 72 million SEK that is currently underway, and his vision for the future.
HoloMonitor Fluorescence Now at Novo Nordisk
PHI recently installed a fluorescence-equipped HoloMonitor® system at Novo Nordisk A/S. The installation is part of a series of test installations to allow experienced HoloMonitor customers to provide feedback regarding functionality and user-friendliness prior to the upcoming product launch.
PHI changes the date for publication of Interim Report 3 2021/22
The reason for the change of date is to allow management and staff to participate in the newly decided rights issue by purchasing shares.